- BiondVax participated in the life science industry’s 17th annual Bio-Europe Spring Conference, held this year in Switzerland
- BiondVax was highlighted as one of the “best ideas” in a NASDAQ-published article after the completion of the conference
- The company’s biobetter nanosized antibody therapies promise stability at high temperatures, superior binding affinity, convenient routes of administration, and cost effective production
The EBD Group’s 17th annual Bio-Europe Spring Conference was held March 20-22, 2023, in Basel, Switzerland. The conference showcased three thematic pillars – the business of biotech, therapeutic insight tracks, and ecosystem influencers. The elite European bio-tech conference featured a mix of keynotes from life science executives, fireside chats, panel discussions, and presentations that allowed attendees to hear the latest industry trends, insights, exciting opportunities, and challenges. A featured presentation by BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company engaged in developing, manufacturing, and commercializing innovative immunotherapeutic products for infectious and autoimmune diseases, highlighted the company’s unique approach to developing biobetter therapeutics targeting diseases with underserved medical needs and large commercial opportunities.
After the Bio-Europe Spring Conference ended, NASDAQ published an article with the best ideas from the event – including BiondVax, who shared a stage with top names like Novartis, Bristol Myers Squibb, Pfizer, and Roche. Investors and attendees of the conference gained exceptional insight into the innovations being made within the industry, including BiondVax’s unique offering of a nanosized antibody (nanobody) therapy pipeline (https://ibn.fm/FMEgg).
BiondVax enjoys an exclusive collaboration with the prestigious Max Plank Society and University Medical Center Göttingen (“UMG”) in Germany to develop a pipeline of innovative nanosized antibody (NanoAb) therapies that address diseases underserved by current treatments and with large growing markets, including COVID-19, asthma, and psoriasis. BiondVax’s NanoAbs offer significant advantages over human monoclonal antibody (“mAb”) and oral therapies currently being used in the industry.
NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that show significant competitive advantages over existing therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration, and cost effective production. These benefits were highlighted in the company’s presentation at the Bio-Europe Spring Conference. BiondVax stressed that NanoAbs offer a more favorable path to market versus the risks associated with traditional drug development.
Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate. It built, owns, and operates a 20,000-square-foot state-of-the-art GMP biologics manufacturing facility that houses its laboratories, production facilities, and offices.
The initial focus of BiondVax’s pipeline is COVID-19, a market estimated to be worth well over $8 billion, as well as treatments for asthma, macular degeneration, psoriasis, and psoriatic arthritis in the future. All treatment areas have validated targets by existing monoclonal antibody therapies and offer large markets growing at attractive compound annual growth rates.
BiondVax’s COVID-19 candidate exhibits a strong competitive edge, neutralizing the omicron variant, while other therapies do not. The treatment created by the company is delivered directly, conveniently, and efficiently to the lungs through inhalation, with preclinical studies showing that the candidate “virtually prevented” COVID-19 in hamsters infected hours later with the virus. BiondVax also reported that its NanoAb candidate “eliminated viral load in the lungs.”
Based on the promising results, BiondVax’s focus on asthma and psoriasis/psoriatic arthritis will begin with the following NanoAbs:
- NanoAbs targeting IL-13 and TSLP as drug candidates for potential asthma treatment
- NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
BiondVax intends to advance its NanoAb innovation from R&D through commercialization leveraging its top-tier pharma leadership team, extensive drug development expertise, GMP biologics manufacturing facility, and its collaboration with the Max Plank Society and UMG. Despite its current small size, with its unique large pharma competencies BiondVax is well-positioned to bring innovative therapies to market.
For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046